NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Dr June M Raine DBE
Chief Executive’s perspective on the year.

On the international stage, our Chairmanship of the Access Consortium has enabled us to promote innovation and expedite approvals across a population of 150 million people.

Full membership in the International Medical Device Regulators Forum and the International Conference on Harmonisation, allows us to contribute to global work on medical devices and influence the development of guidelines to the benefit of UK patients.

It would be remiss not to acknowledge that this has come with challenges. We have seen a high level of turnover in staff during 2022/23. Whilst this has now returned to normal levels, it had an impact on our ability to ensure predictable levels of operational performance. Our work to address legacy systems and processes to embed best practice continues. With our new structures, processes and technology being implemented, we continue to challenge, critique and evolve our culture to meet our vision of becoming a world-leading, proactive and enabling regulator. All of this and more is captured in our new Corporate Plan 2023-2026.

📰 Our Annual Report for 2022/23 is out now.

From cutting-edge science and supporting innovation to criminal enforcement and improving patient access, read all about the MHRA’s work over the past year.

Check out our Annual Report here 👉 https://t.co/X0jxsQJFWV pic.twitter.com/OLk30JECrA

— MHRAgovuk (@MHRAgovuk) July 19, 2023